Tailoring adjuvant treatments for the individual patient with luminal breast cancer

Research output: Contribution to journalArticlepeer-review


Estrogen Receptor-positive/HER-2 negative breast cancers represent a heterogeneous group of tumors. Luminal A and B tumor subtypes can be identified through immunohistochemical assessment of estrogen and progesterone receptor, Ki-67 and HER-2 status. Patients with high levels of expression of steroid hormone receptors and low proliferation (Luminal A) are commonly cured with endocrine therapy alone. Patients with doubtful endocrine responsiveness or with high proliferation index (Luminal B/Her-negative) require the addition of chemotherapy to the best endocrine therapy. Controversies still exist on the identification of those patients who do not benefit from chemotherapy. Tailored adjuvant treatments should be considered in the therapeutic algorithm of patients with luminal tumors.

Original languageEnglish
Pages (from-to)703-714
Number of pages12
JournalHematology/Oncology Clinics of North America
Issue number4
Publication statusPublished - Aug 2013


  • Adjuvant therapy
  • Breast cancer
  • Endocrine therapy
  • Gene assay
  • Luminal A
  • Luminal B

ASJC Scopus subject areas

  • Oncology
  • Hematology


Dive into the research topics of 'Tailoring adjuvant treatments for the individual patient with luminal breast cancer'. Together they form a unique fingerprint.

Cite this